Baseline TREM-1 Whole Blood Gene Expression Does Not Predict Response to Adalimumab Treatment in Patients with Ulcerative Colitis or Crohn's Disease in the SERENE Studies.

Bram VerstocktValerie PivorunasNaim Al MahiNizar SmaouiHeath GuayNicholas A KennedyJames R GoodhandSimeng LinBenjamin Y H BaiStephen B HanauerMarc FerranteJulian PanésSéverine Vermeire

Published in: Journal of Crohn's & colitis (2023)

Baseline TREM-1 gene expression did not uniformly predict adalimumab response in SERENE clinical trials. Further research is needed to identify potential blood-based biomarkers predictive of response to anti-TNF therapy in patients with IBD.

Keyphrases

ulcerative colitis
gene expression
rheumatoid arthritis
clinical trial
dna methylation
juvenile idiopathic arthritis
hidradenitis suppurativa
stem cells
randomized controlled trial
phase ii
combination therapy
risk assessment
bone marrow